Claims

1. Use of a pharmaceutical composition comprising *Bifidobacterium longum* IM55 KCCM11961P in the manufacture of a medicament for treating allergic diseases, autoimmune diseases or inflammatory diseases.

2. The use according to claim 1, wherein said *Bifidobacterium longum* IM55 KCCM11961P is a live cell body thereof, a dead cell body thereof, a culture product thereof, a crushed product thereof or an extract thereof.

3. The use according to claim 1, wherein said the pharmaceutical composition further comprises a live cell body of *Lactobacillus plantarum* IM76 KCCM11962P, a dead cell body thereof, a culture product thereof, a crushed product thereof or an extract thereof.

4. The use according to claim 1, wherein said allergic diseases are at least one selected from the group comprising rhinitis, atopy, asthma, atopic dermatitis, allergic conjunctivitis, allergic otitis media, hives and anaphylactic shock.

5. The use according to claim 1, wherein the inflammatory diseases is colitis.

6. The use according to claim 1, wherein said pharmaceutical composition further comprises at least one selected from the group including chitosan, inulin and citrus pectin.

7. Use of a food composition comprising *Bifidobacterium longum* IM55 KCCM11961P in the manufacture of a medicament for alleviating allergic diseases, autoimmune diseases or inflammatory diseases.

8. The use according to claim 7, wherein said *Bifidobacterium longum* IM55 KCCM11961P is a live cell body thereof, a dead cell body thereof, a culture product thereof, a crushed product thereof or an extract thereof.

9. The use according to claim 7, wherein the food composition further comprises

a live cell body of *Lactobacillus plantarum* IM76 KCCM11962P, a dead cell body thereof, a culture product thereof, a crushed product thereof or an extract thereof.

10. The use according to claim 7, wherein said allergic diseases are at least one selected from the group comprising rhinitis, atopy, asthma, atopic dermatitis, allergic conjunctivitis, allergic otitis media, hives and anaphylactic shock.

11. The use according to claim 7, wherein the inflammatory disease is colitis.

12. The use according to claim 7, wherein said pharmaceutical composition comprises at least one selected from the group including chitosan, inulin and citrus pectin.